Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of the Combination of MLN8237 and Gemcitabine in Advanced Solid Tumors With Emphasis on Pancreatic Cancer

NCT01924260 is registered in ClinicalTrials.gov with Edward Kim as lead sponsor.

NCT NCT01924260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01924260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of the Combination of MLN8237 and Gemcitabine in Advanced Solid Tumors With Emphasis on Pancreatic Cancer
Lead sponsor
Edward Kim
Phase
Phase 1
Overall status
Completed
Start date
August 9, 2013
Completion date
February 8, 2017
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acinar cell adenocarcinoma of the pancreas, duct cell adenocarcinoma of the pancreas, recurrent pancreatic cancer, stage iii pancreatic cancer, stage iv pancreatic cancer, unspecified adult solid tumor, protocol specific